EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
Organizational focus on DURAVYUTM Phase 3 DME program; trials fully enrolled with topline data exp
Organizational focus on DURAVYUTM Phase 3 DME program; trials fully enrolled with topline data exp